help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wojcik, J.
Right arrow Articles by Finidori, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wojcik, J.
Right arrow Articles by Finidori, J.
The Journal of Clinical Endocrinology & Metabolism Vol. 83, No. 12 4481-4489
Copyright © 1998 by The Endocrine Society


Original Studies

Four Contiguous Amino Acid Substitutions, Identified in Patients with Laron Syndrome, Differently Affect the Binding Affinity and Intracellular Trafficking of the Growth Hormone Receptor1

Jérôme Wojcik, Mary Anne Berg2, Nazario Esposito, Mitchell E. Geffner, Nadia Sakati, Edward O. Reiter, Steven Dower, Uta Francke, Marie-Catherine Postel-Vinay and Joëlle Finidori

INSERM U-344, Endocrinologie Moléculaire, Faculté Necker-Enfants Malades (J.W., N.E., M.-C.P.-V., J.F.), 75015 Paris, France; Howard Hughes Medical Institute and Department of Genetics, Stanford University Medical Center (M.A.B., U.F.), Stanford, California 94305; the Department of Pediatrics, University of California Children’s Hospital (M.E.G.), Los Angeles, California 90095-1752; the Department of Pediatrics, King Faisal Specialist Hospital (N.S.), Riyadh 11211, Saudi Arabia; the Department of Pediatrics, Baystate Medical Center Childrens Hospital (E.O.R.), Springfield, Massachusetts 01199; and the Division of Molecular and Genetic Medicine, The Medical School, University of Sheffield, Royal Hallamshire Hospital (S.D.), Sheffield, United Kingdom S10 2JF

Address all correspondence and requests for reprints to: Dr. Joëlle Finidori, INSERM U-344, Faculté de Médecine Necker-Enfants Malades, 156 rue de Vaugirard, 75730 Paris Cedex 15, France. E-mail: finidori{at}necker.fr

We have analyzed the GH receptor (GHR) gene in four individuals with Laron syndrome, and a missense mutation was identified for each patient in the extracellular domain of the GHR (D152H, I153T, Q154P, and V155G). The D152H mutation was previously reported. We have reproduced the three novel mutations in the GHR complementary DNA and analyzed their consequences in human 293 transfected cells. In cells expressing the I153T and V155G mutants, binding of [125I]human GH at the cell surface was very low, whereas binding to total membrane fractions was much less affected, suggesting impaired cell surface expression. Binding assays with cells expressing the Q154P mutant revealed severe defects both at the cell surface and in total particulate membrane fractions. Immunofluorescence experiments confirmed that cell surface expression of the three mutants was altered, and colocalization studies suggested that most of the mutant receptors are retained in the endoplasmic reticulum. Endoglycosidase H resistance tests also indicated that the majority of I153T and V155G GHRs are trapped in the endoplasmic reticulum. Thus, mutations on contiguous amino acids of the GHR result in various defects. The I153T, Q154P, and V155G mutations mainly affect intracellular trafficking and binding affinity of the receptor, whereas the D152H mutation affects receptor expression, dimerization, and signaling.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
P. Fang, R. Girgis, B. M. Little, K. L. Pratt, J. Guevara-Aguirre, V. Hwa, and R. G. Rosenfeld
Growth Hormone (GH) Insensitivity and Insulin-Like Growth Factor-I Deficiency in Inuit Subjects and an Ecuadorian Cohort: Functional Studies of Two Codon 180 GH Receptor Gene Mutations
J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 1030 - 1037.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
D. N. Hebert and M. Molinari
In and Out of the ER: Protein Folding, Quality Control, Degradation, and Related Human Diseases
Physiol Rev, October 1, 2007; 87(4): 1377 - 1408.
[Abstract] [Full Text] [PDF]


Home page
J EndocrinolHome page
M Maamra, A Milward, H Z. Esfahani, L P Abbott, L A Metherell, M O Savage, A J L Clark, and R J M Ross
A 36 residues insertion in the dimerization domain of the growth hormone receptor results in defective trafficking rather than impaired signaling
J. Endocrinol., February 1, 2006; 188(2): 251 - 261.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Tiulpakov, P. Rubtsov, I. Dedov, V. Peterkova, O. Bezlepkina, G. P. Chrousos, and Z. Hochberg
A Novel C-Terminal Growth Hormone Receptor (GHR) Mutation Results in Impaired GHR-STAT5 But Normal STAT-3 Signaling
J. Clin. Endocrinol. Metab., January 1, 2005; 90(1): 542 - 547.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
Z. Laron
Laron Syndrome (Primary Growth Hormone Resistance or Insensitivity): The Personal Experience 1958-2003
J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1031 - 1044.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Milward, L. Metherell, M. Maamra, M. J. Barahona, I. R. Wilkinson, C. Camacho-Hubner, M. O. Savage, C. M. Bidlingmaier, A. J. L. Clark, R. J. M. Ross, et al.
Growth Hormone (GH) Insensitivity Syndrome due to a GH Receptor Truncated after Box1, Resulting in Isolated Failure of STAT 5 Signal Transduction
J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1259 - 1266.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
E. M. Kofoed, V. Hwa, B. Little, K. A. Woods, C. K. Buckway, J. Tsubaki, K. L. Pratt, L. Bezrodnik, H. Jasper, A. Tepper, et al.
Growth Hormone Insensitivity Associated with a STAT5b Mutation
N. Engl. J. Med., September 18, 2003; 349(12): 1139 - 1147.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
C. K. Buckway, J. Guevara-Aguirre, K. L. Pratt, C. P. Burren, and R. G. Rosenfeld
The IGF-I Generation Test Revisited: A Marker of GH Sensitivity
J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5176 - 5183.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
K.-C. Leung, N. Doyle, M. Ballesteros, M. J. Waters, and K. K. Y. Ho
Insulin Regulation of Human Hepatic Growth Hormone Receptors: Divergent Effects on Biosynthesis and Surface Translocation
J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4712 - 4720.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
K. Iida, Y. Takahashi, H. Kaji, N. Onodera, M. O. Takahashi, Y. Okimura, H. Abe, and K. Chihara
The C422F Mutation of the Growth Hormone Receptor Gene Is Not Responsible for Short Stature
J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 4214 - 4219.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
M. Maamra, J. Finidori, S. Von Laue, S. Simon, S. Justice, J. Webster, S. Dower, and R. Ross
Studies with a Growth Hormone Antagonist and Dual-fluorescent Confocal Microscopy Demonstrate that the Full-length Human Growth Hormone Receptor, but Not the Truncated Isoform, Is Very Rapidly Internalized Independent of Jak2-Stat5 Signaling
J. Biol. Chem., May 21, 1999; 274(21): 14791 - 14798.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1998 by The Endocrine Society